Insulin Icodec (Awiqli)

Abstract

CADTH recommends that Awiqli be reimbursed by public drug plans for the once-weekly treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycemic control if certain conditions are met. Awiqli should only be covered to treat adults with T2DM whose glycated hemoglobin (hemoglobin A1C) is between 7.0% and 11.0% (inclusive). To ensure cost-effectiveness, the total drug cost of Awiqli should not exceed the total drug cost of the least costly long-acting basal insulin analogue.